Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
- PMID: 9400932
- PMCID: PMC2228166
- DOI: 10.1038/bjc.1997.568
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Comment on
-
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.Br J Cancer. 1997;76(11):1494-9. doi: 10.1038/bjc.1997.584. Br J Cancer. 1997. PMID: 9400948 Free PMC article. Clinical Trial.
-
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.Br J Cancer. 1997;76(11):1500-8. doi: 10.1038/bjc.1997.585. Br J Cancer. 1997. PMID: 9400949 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
